Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) passed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of C$1.39 and traded as low as C$1.18. Oncolytics Biotech shares last traded at C$1.21, with a volume of 144,265 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Raymond James raised Oncolytics Biotech to a "moderate buy" rating in a research note on Thursday, November 14th.
Get Our Latest Stock Report on Oncolytics Biotech
Oncolytics Biotech Stock Down 3.3 %
The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The firm's fifty day moving average is C$1.33 and its 200 day moving average is C$1.39. The stock has a market cap of C$89.93 million, a P/E ratio of -3.08 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
